Novalis Biotech closes biotech fund at 25m
Early-stage venture capital investor Novalis Biotech has closed its Biotech Acceleration Fund at 25m to drive growth of translational medicine start-ups.
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1328 entries already.
Early-stage venture capital investor Novalis Biotech has closed its Biotech Acceleration Fund at 25m to drive growth of translational medicine start-ups.
Swedish Cellink AB has announced a bid of $110m to take over all shares of Discover Echo Inc., 11% of which to be paid in newly issued shares.
Major CDMO Catalent has swallowed German RheinCell Therapeutics GmbH, an iPSC specialist, to expand its offerings in cell and gene therapies.
In an effort to ban AI tools for facial recognition, the EU risks to block European medical geneticists to recognise genetic diseases.
NeuVasQ Biotechnologies has raised 20m through a Series A investment to advance its technology platform that restores the integrity of the blood-brain barrier in acute neurological disorders.
Coriolis Pharma will launch operations at its currently expanded ATMP development facilities by Q4/2021.
CARB-X is funding Swiss pharma company BioVersys with $15.2m to develop a new class of antibiotics to treat infections caused by multidrug-resistant pathogens.
Lonza will expand its production capacity of Modernas mRNA vaccine mRNA1273 at its manufacturing site in Geelen, the Netherlands.
The European Medicines Agency (EMA) has given the green light for vaccination of adolescents with Biontech’s COVID-19 vaccine Comirnaty (BNT162b2).
Senti Biosciences and Bayer subsidiary BlueRock Therapeutics form strategic partnership to combine iPSC and gene circuit-engineered cell therapy platforms.